Cargando…
Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
OBJECTIVES: Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for lowering IOP. This study compared the safety a...
Autores principales: | Wang, Yulong, Liao, Yue, Nie, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Medicina / USP
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688071/ https://www.ncbi.nlm.nih.gov/pubmed/33263632 http://dx.doi.org/10.6061/clinics/2020/e1874 |
Ejemplares similares
-
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018) -
Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018) -
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018) -
Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019) -
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)